Contact this trialFirst, we need to learn more about you.
Checkpoint Inhibitor
Nivolumab + Hydroxychloroquine / Ipilimumab for Melanoma
Recruiting3 awardsPhase 1 & 2
Philadelphia, Pennsylvania
This trial is testing a combination of hydroxychloroquine with two immune-boosting drugs, nivolumab and ipilimumab, in patients with advanced skin cancer. The goal is to see if these combinations are safe and effective. Hydroxychloroquine helps the immune system, while nivolumab and ipilimumab help the body attack cancer cells. Nivolumab and ipilimumab have been used together to treat various cancers, including advanced melanoma, with improved response rates.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service